Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4977 - Synergistic effect of Vismodegib and Cisplatin in NSCLC models via autophagy


11 Sep 2017


Poster display session


Cancer Biology;  Thoracic Malignancies


Federica Papaccio


Annals of Oncology (2017) 28 (suppl_5): v1-v21. 10.1093/annonc/mdx361


F. Papaccio1, L. Mele2, C.M. Della Corte1, D. Liccardo2, M. La Noce3, V. Desiderio3, V. Tirino3, F. Ciardiello1, F. Morgillo1

Author affiliations

  • 1 Medical Oncology, Department Of Clinical And Experimental Medicine "f. Magrassi", University of Campania "Luigi Vanvitelli", 80131 - Naples/IT
  • 2 Department Of Experimental Medicine - Section Of Biotechnology, Medical Histology And Molecular Biology, University of Campania "Luigi Vanvitelli", Napoli/IT
  • 3 Department Of Experimental Medicine - Section Of Biotechnology, Medical Histology And Molecular Biology, University of Campania "Luigi Vanvitelli", 80138 - Napoli/IT


Abstract 4977


Platinum-based chemotherapy still represents the standard first-line approach for NSCLC patients, although primary or secondary resistance is frequently observed. Recently the Shh pathway has been associated with resistance to platinum-based chemotherapy in NSCLC. The aim of this work is to investigate whether a combined treatment with cisplatin and the Hedgehog-pathway inhibitor vismodegib could potentiate the anti-tumour effect and to explore possible mechanisms of this synergy.


Two Human NCSLC cell lines A549 and H460 were treated with single agent Cisplatin, single agent Vismodegib and a combination of the two drugs. MTT cytotoxicity assays were performed and the data were analysed with CompuSyn software. Experiments of apoptosis and cell cycle were done by using flow cytometer. Immunofluorescence with lysoTracker as well as western blot (WB) analysis for the LC3B protein were performed to analyse autophagy.


The CompuSyn analysis showed an important synergistic effect of cisplatin + Vismodegib. Combined treatment induced a significant increase in cellular apoptosis compared with single agent cisplatin. The cell cycle analyses revealed a block in S-phase with the combination treatment. The lysoTracker immunofluorescence assay showed that cisplatin induces an increase of autophagy, while the combination with vismodegib strongly reduces it, finally reverting this effect. These findings were confirmed by WB analysis for LC3B which is significantly increased by single agent cisplatin and reduced by the combined treatment.


Combined treatment with cisplatin and vismodegib has a synergistic effect with an increase in cancer cell apoptosis. Autophagy has been described as a mechanism through which cancer cells escape cisplatin-induced cytotoxicity. Combining cisplatin with vismodegib leads to an inhibition of autophagy, so that it could suggest a new therapeutic approach.

Clinical trial identification

Legal entity responsible for the study

Università della Campania “Luigi Vanvitelli”




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.